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 Obesity is an important risk factor for a number of chronic diseases that impose a 
huge burden on individuals and society. Recently, it has become clear that adipose 
tissue secreted products may play a significant role in mediating many obesity related 
diseases including diabetes. Thus, in addition to being an energy depot, the adipocyte 
is a highly active cell secreting a plethora of factors with profound effects on a 
number of organs and systems. The study of these factors and their endocrine effects 
has become a rapidly evolving and dynamic area of endocrinology. One paradigm for 
explaining the deleterious effects of adipokines is related to the sheer increase in 
adipose tissue mass in obesity. When preadipocytes differentiate to become mature 
adipocytes, they acquire the ability to synthesize numerous proteins, including 
cytokines, growth factors, and hormones that are involved in overall energy 
homeostasis and various paracrine effects. In health, these proteins do not spill over 
significantly into the circulation. In obesity, the massive increase in fat mass leads to a 
significant increase in circulation of many adipose tissue secreted factors that may 
have pathogenic effects. For example, the increase in circulating angiotensin II in 
obesity is related at least in part due to excess adiposity and may mediate 
hypertension (1). In recent years, adipose tissue has been found to be a major source 
of many proteins that may directly contribute to vascular injury, diabetes, and 
atherogenesis (2). These pro-inflammatory adipokines include TNF-α, IL-6, leptin, 
plasminogen activator inhibitor-1 (PAI-1), angiotensinogen, & resistin, amongst many 
others. In contrast, the adipokine adiponectin confers protection against inflammation, 
atherogenesis and obesity-linked insulin resistance.  
A recent addition to the now formidable list of contenders as a pivotal factor in 
mediating obesity driven diabetes is retinol binding protein 4 (RBP4). RBP4 has been 
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proposed to be a marker for diabetes and also potentially a target for therapy. It is still 
too early to determine whether it will fulfil this promise. What do we know about 
RBP-4 so far? 
RBP4 (retinol binding protein-4) is a protein that is the specific carrier for 
retinol (vitamin A alcohol) in the blood. It is not a recently described protein, one of 
the earliest descriptions appeared back in 1987 (3). It is one of a large number of 
proteins solubilize and stabilize their hydrophobic and labile metabolites of retinoids 
in aqueous spaces both in extra and intra-cellular spaces (4). RBP4 is normally bound 
in the circulation to transthyretin. Its physiological function appears to be to bind 
retinol and prevent its loss through the kidneys. Deficiency of RBP-4 in humans has 
been described in a girl with intermittent orange discoloration of her palms, soles, and 
face and with carotenemia associated with persistently low levels of both vitamin A 
and serum-specific retinol-binding protein. It is also associated with night vision 
problems (5). There is, as yet, no report of any change in RBP-4 levels or insulin 
sensitivity with changes in dietary Vitamin A. Although, RBP4 was known as the 
binding protein for retinol, that it is secreted by adipocytes has only recently been 
discovered (6). Abel et al, studied GLUT-4 knock-out mice and suggested that 
adipose tissue serves as a glucose sensor and modulates systemic glucose metabolism 
through release of a substance in response to decreased intracellular glucose 
concentrations (6, 7). Further transgenic mice studies manipulating GLUT4 
expression has shown corresponding inverse changes in RBP4 adipose tissue 
expression and circulating RBP4 levels (8, 9). These studies demonstrated a 
mechanism by which adipocytes can modulate glucose metabolism in muscle. There 
are multiple mechanisms described by which RBP4 can effect changes in glucose 
utilisation. Retinol-dependent mechanisms may utilise different retinol isomers to 
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affect insulin sensitivity and insensitivity (8, 10); whilst retinol independent 
mechanisms may affect metabolism through cell surface receptors (8). The cell-
surface protein megalin (gp320) is the only RBP4 receptor known so far, but the 
reported binding affinity is low. However, RBP4 binds to a wide range of retinoids 
and is likely to transport other lipophilic molecules that may mediate its effect on 
glucose (8, 9).  
A potential link between RBP4 and human diabetes was suggested by a report 
that revealed that RBP4 was elevated in insulin-resistant mice and humans with 
obesity and T2DM (8). RBP4 levels were normalized by rosiglitazone, establishing a 
link with insulin sensitivity. Studies in transgenic rodent models showed 
overexpression of human RBP4 or injection of recombinant RBP4 induced insulin 
resistance in mice, whereas RBP4 knock-out mice showed enhanced insulin 
sensitivity. RBP4 was shown to induce expression of the gluconeogenic enzyme 
PEPCK (phosphoenolpyruvate carboxykinase) and decreased insulin signaling in 
muscle. Thus, Yang et al.  concluded that RBP4 is an adipocyte-derived 'signal' that 
may contribute to the pathogenesis of T2DM (8). Therefore, lowering RBP4 has been 
proposed as a new potential therapy for diabetes. There is already a drug known to 
lower RBP-4.  Fenretinide, a synthetic retinoid that increases urinary RPB4 excretion, 
which reduces serum RBP4 levels and improves insulin action in obese mice, may 
have therapeutic potential in T2DM. It is currently being evaluated in trials for, basal 
cell carcinoma, childhood leukemia and ovarian cancer (11).  
Not all proteins shown to be relevant to diabetes in rodent models have proved 
their role in human diabetes. Indeed, this field of research is littered with examples of 
discrepancies between murine and human studies (12-13). Whilst the foregoing 
account would suggest a major role for RBP4 in diagnosis and treatment of human 
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diabetes, more recent reports have, however, not been so encouraging at least for 
human diabetes. For example, Janke et al, (7) suggest that in human abdominal 
subcutaneous (AbdSc) adipose tissue RBP4 mRNA is downregulated in obese 
women, whilst circulating RBP4 concentrations remain similar in lean, overweight, 
and obese women. They suggest methodological differences including techniques 
used in the measurement as well as differences in the population studied may account 
for the discrepancies (7). A more recent report examining different techniques for the 
measurement of RBP4 protein Graham et al, casts light on some of the pitfalls in the 
interpretation of various studies. They demonstrated that most ELISAs undervalue 
human serum RBP4 levels, and furthermore, sub-optimal recognition of full length 
RBP4 and poor linearity of dilution also limited assay utility (14). On the basis of his 
studies, he recommends use of quantitative Western blotting using antibodies to full 
length RBP4 as the method of choice where possible. This is however, clearly not a 
viable option for large scale studies. Thus, whilst the early studies clarified a 
potentially interesting role for RBP4 in glucose metabolism, further studies suggest 
differences between rodent and human physiology and also significant redundancy in 
the system as clearly a number of other factors may also play a role.   
In the current issue of JCE & M, Yao-Borengasser and co-workers have 
evaluated RBP4 in human subjects and also report effects of pioglitazone on RBP4 
mRNA in AbdSc adipose tissue. From their findings it is clear that whilst the human 
adipocyte contributes to the production of RBP4, neither AbdSc RBP4 mRNA 
expression nor circulting RBP-4 levels show any correlation with body mass index. 
Insulin sensitive subjects showed a tendency to lower RBP4 compared to insulin 
resistant subjects, but this was not statistically significant (15). This observation 
would cast doubt on the utility of this protein as a biomarker to identify those at risk 
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for diabetes, at least when used on its own. The authors also identified positive 
correlations between RBP4 and CD68 in adipose tissue suggesting a role for RBP4 in 
inflammation, which may have local affects with adipose tissue rather than a systemic 
effect.  
Yao-Borengasser et al, also investigated the effects of the insulin sensitizer, 
pioglitazone, on RBP4 expression in subjects with impaired glucose tolerance. 
Surprisingly, they showed that mRNA expression increased following pioglitazone in 
both adipose tissue and muscle, which is in direct contrast to the reported effects of 
rosiglizone treatment on RBP4 mRNA levels in adipose tissue from Glut4-/- mice  (9, 
15). One limitation of this study is that they have not assessed protein expression or 
secretion by adipocytes following treatment with pioglitazone. Serum RBP4 did not 
show a rise following pioglitazone. Such findings with TZDs have also been noted 
with other adipokines (16-20). Thus, understanding the protein expression profile for 
RBP4 within adipose tissue and its regulation may shed further light of the role of the 
adipokine. It is possible that other tissues may contribute to serum RBP4 in human 
subjects. 
Whilst understanding the molecular mechanism of action for adipokines has 
proved to be a challenging area of research, it is clear that a better understanding of 
their pathophysiology and mechanism of action may lead to both the discovery of new 
diagnostic tests and potentially more effective clinical therapies. Such advances in 
medicine would be welcome to help target therapy better and to treat those at highest 
risk. Clearly, considerable work is required to prove the added value of such new 
diagnostic tests or therapies over what we have today. For the majority with obesity, it 
is however, changes in lifestyle that are needed. Reduction in adipose tissue mass 
leads to favorable changes in adipokine profiles that will in turn assist in mitigating 
 6
the malign consequences of obesity. Thus, whilst progress in this field of 
endocrinology is exciting, clinicians still need to focus on efforts to prevent and treat 
obesity more effectively.  
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